- Home
- GILD vs BUD Comparison
GILD vs BUD Comparison
Compare GILD & BUD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- BUD
- Stock Information
- Founded
- GILD 1987
- BUD 1366
- Country
- GILD United States
- BUD Belgium
- Employees
- GILD N/A
- BUD N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- BUD Beverages (Production/Distribution)
- Sector
- GILD Health Care
- BUD Consumer Staples
- Exchange
- GILD Nasdaq
- BUD Nasdaq
- Market Cap
- GILD 131.5B
- BUD 121.9B
- IPO Year
- GILD 1992
- BUD N/A
- Fundamental
- Price
- GILD $104.54
- BUD $65.63
- Analyst Decision
- GILD Buy
- BUD Buy
- Analyst Count
- GILD 27
- BUD 3
- Target Price
- GILD $105.32
- BUD $64.00
- AVG Volume (30 Days)
- GILD 10.4M
- BUD 3.1M
- Earning Date
- GILD 04-24-2025
- BUD 05-07-2025
- Dividend Yield
- GILD 3.02%
- BUD 1.60%
- EPS Growth
- GILD N/A
- BUD 10.00
- EPS
- GILD 0.38
- BUD 2.86
- Revenue
- GILD $28,754,000,000.00
- BUD $59,768,000,000.00
- Revenue This Year
- GILD $1.80
- BUD $1.64
- Revenue Next Year
- GILD $3.83
- BUD $4.53
- P/E Ratio
- GILD $275.11
- BUD $22.17
- Revenue Growth
- GILD 6.04
- BUD 0.65
- 52 Week Low
- GILD $62.07
- BUD $45.94
- 52 Week High
- GILD $119.96
- BUD $67.49
- Technical
- Relative Strength Index (RSI)
- GILD 43.51
- BUD 67.98
- Support Level
- GILD $97.32
- BUD $57.97
- Resistance Level
- GILD $107.18
- BUD $63.47
- Average True Range (ATR)
- GILD 3.94
- BUD 1.38
- MACD
- GILD -0.45
- BUD 0.23
- Stochastic Oscillator
- GILD 41.42
- BUD 96.60
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.